We aimed to evaluate the prevalence of metabolic syndrome (MS) in a group of obese children and adolescents in Zhejiang in the south of China, and to compare risk factors such as insulin resistance, adiponectin level and impaired glucose tolerance (IGT) etc with that of simple obese group (SOB) and non-obese healthy group, and also to evaluate the effect of metformin and lifestyle intervention in MS group by up to a 3-month follow-up.
Three hundred and forty eight moderately or severely obese adolescents aged between 7 and 16 years were enrolled. Oral glucose tolerance test (OGTT), biochemical indicators, blood pressure and body mass index (BMI) were assessed in all of them. Three subgroups were selected (MS group, SOB and healthy control). Adiponectin levels, Whole body insulin sensitive index (WBISI), homeostasis model of insulin resistance (HOMA-IR), plasma lipid and blood pressure were compared in these three groups. Thirty out of thirty-six MS subjects with age over 10 years received metformin treatment combined with lifestyle modification.
(1) The prevalence of MS was 10.34% among all obese subjects, which increased with the severity of obesity and reached 22.1% in severely obese children and adolescents. The occurrence of more than one complication reached 72.13%. The incidence of type 2 diabetes and IGT were 1.44 and 1.44% respectively. (2) BMI, waist-to-hip ratio (WHR) and HOMA-IR increased stepwise in the control group, SOB and MS group, whereas serum adiponectin and WBISI decreased stepwise (all P<0.01). Systolic pressure, triglyceride, total cholesterol, low-density lipoprotein cholesterol and postprandial 2-h blood glucose in the MS group increased significantly compared to those in control and SOBs (all P<0.01). A correlation analysis showed that serum levels of adiponectin and WBISI were associated with the components of MS (all P<0.05). (3) After metformin and lifestyle intervention, clinical symptoms were ameliorated, serum adiponectin levels were actually increased and HOMA-IR was dropped in 20/30 MS children who had finished a 3-months follow-up (all P<0.01).
The prevalence of MS in severely obese children and adolescents in Zhejiang area has reached a high level. Insulin resistance and hypoadiponectinemia were found in these MS children. Metformin combined with lifestyle modification was confirmed to be efficient and safe in treating the obese adolescents with MS.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB . The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003; 163: 427–436.
Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.
Tong W, Lai H, Yang C, Ren S, Dai S, Lai S . Age, gender and metabolic syndrome-related coronary heart disease in U.S adults. Int J Cardiol 2005; 104: 288–291.
Kaur H, Hyder ML, Poston WS . Childhood overweight: an expanding problem. Treat Endocrinol 2003; 2: 375–388. Review.
Kohen-Avramoglu R, Theriault A, Adeli K . Emergency of the metabolism syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. Clin Biochem 2003; 36: 413–420.
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–1599.
Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K . Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 2003; 26: 705–710.
Yohei O, Toru K, Keisuke N, Makoto H, Yukie T, Makoto U . Useful of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children. Hypertens Res 2005; 28: 51–57.
Bestermann W, Houston MC, Basile J, Egan B, Ferrario CM, Lackland D et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005; 329: 292–305. Review.
Ya-mei H, Zai-fang J . Practical Pediatric Textbook of Fu-tang Zhu 7th edn. People's Hygienic Publish Society: Beijing, 2000. pp. 27–30 553,1414, 2047, 2687.
Metabolic syndrome study group of Chinese Diabetes Association. Proposal of metabolic syndrome by Chinese Diabetes Association. Chinese J Diabetes 2004; 12: 156–161.
Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362–2374.
Alberti KG, Zimmet PZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998; 15: 539–553.
Brunt EM . Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3–20.
Wieckowska A, Feldstein AE . Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr 2005; 17: 636–641.
Sung RY, Tong PC, Yu CW, Lau PW, Mok GT, Yam MC et al. High prevalence of insulin resistance and metabolic syndrome in overweight/obese preadolescent Hong Kong Chinese children aged 9–12 years. Diabetes Care 2003; 26: 250–251.
Yoshinaga M, Tanaka S, Shimago A, Sameshima K, Nishi J, Nomura Y et al. Metabolic syndrome in overweight and obese Japanese children. Obese Res 2005; 13: 1135–1140.
Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH . Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 2003; 157: 821–827.
Otto Buczkowska E . Insulin resistance and hyperinsulinemia – risk factors of the metabolic syndrome in the pubertal population. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 2005; 11: 109–114.
Woo JG, Dolan LM, Daniels SR, Goodman E, Martin LJ . Adolescent sex differences in adiponectin are conditional on pubertal development and adiposity. Obes res 2005; 13: 2095–2101.
Wang C-L, Liang L, Fu J-F, Hong F . Comparison of methods to detect insulin resistance in obese children and adolescents. J Zhejiang Univ: Med Sci 2005; 34: 316–319.
Yeckel CW, Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004; 89: 1096–1101.
Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004; 89: 4053–4061.
Matsuzawa Y . Adipocytokines and metabolic syndrome. Semin Vasc Med 2005; 5: 34–39. Review.
Nemet D, Wang P, Funahashi T, Matsuzawa Y, Tanaka S, Engelman L et al. Adipocytokines, body composition, and fitness in children. Pediatr Res 2003; 53: 148–152.
Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 2003; 11: 1072–1079.
Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005; 111: 1999–2012.
Kobayashi K . Adipokines: therapeutic targets for metabolic syndrome. Curr Drug Targets 2005; 6: 525–529. Review.
Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006; 21: 80–89.
Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al., Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611–619.
Benavides S, Striet J, Germak J, Nahata MC . Efficacy and safety of hypoglycemic drugs in children with type 2 diabetes mellitus. Pharmacotherapy 2005; 25: 803–809.
Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ . Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002; 25: 89–94.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139–146.
Santana LF, de Sa MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM . Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol 2004; 19: 88–96.
Hundal RS, Inzucchi SE . Metformin: new understandings, new uses. Drugs 2003; 63: 1879–1894. Review.
Mehnert H . Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2): S259–S264. Review.
We thank the nursing staff of our endocrinology department for their dedicated care of these young patients during the evaluations and collections of blood samples. We are grateful to Drs You-jun Jiang, Guan-pin Dong and Yun Li for their exceptional care and organization. We also thank Li-qin Chen for her assay expertise and my English teacher PD Andrews for his contribution to English writing checking. This study was supported by the Zhejiang Science and Technology Grants (2005C24001, 2004C30064) and Zhejiang Provincial Medical and Hygiene Technological Fund for Outstanding Young Adults (2003QN012).
About this article
Cite this article
Fu, JF., Liang, L., Zou, CC. et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int J Obes 31, 15–22 (2007). https://doi.org/10.1038/sj.ijo.0803453
- metabolic syndrome
- children and adolescents
Childhood obesity prevention through a community-based cluster randomized controlled physical activity intervention among schools in china: the health legacy project of the 2nd world summer youth olympic Games (YOG-Obesity study)
International Journal of Obesity (2018)
A longitudinal study of serum insulin and insulin resistance as predictors of weight and body fat gain in African American and Caucasian children
International Journal of Obesity (2017)
Association between obesity and metabolic co-morbidities among children and adolescents in South Korea based on national data
BMC Public Health (2014)
International Journal of Obesity (2014)